NASDAQ: BBLG
Bone Biologics Corp Stock

$0.84-0.01 (-1.18%)
Updated Mar 27, 2025
BBLG Price
$0.84
Fair Value Price
$2.19
Market Cap
$2.75M
52 Week Low
$0.71
52 Week High
$4.25
P/E
-0.17x
P/B
0.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.11M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$4M
Beta
0.6
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

BBLG Overview

Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using recombinant human protein. The company's NELL-1/DBX product is an osteostimulative recombinant protein that provides target-specific control over bone regeneration. It is developing the NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease. The company was founded in 2004 and is headquartered in Burlington, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BBLG's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
BBLG
Ranked
Unranked of 108

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$9.09A
$23.64A
$18.99A
View Top Medical Device Stocks

Be the first to know about important BBLG news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BBLG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BBLG ($0.84) is undervalued by 61.58% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BBLG ($0.84) is significantly undervalued by 61.58% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BBLG due diligence checks available for Premium users.

Valuation

BBLG fair value

Fair Value of BBLG stock based on Discounted Cash Flow (DCF)

Price
$0.84
Fair Value
$2.19
Undervalued by
61.67%
BBLG ($0.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BBLG ($0.84) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BBLG price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.17x
Industry
41.37x
Market
31.08x

BBLG price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.79x
Industry
3.97x
BBLG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BBLG's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
BBLG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.9M
Liabilities
$377.7k
Debt to equity
0.11
BBLG's short-term assets ($3.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBLG's short-term assets ($3.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBLG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BBLG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.4M
Investing
$0.0
Financing
$1.1M
BBLG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BBLG vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BBLG$2.75M-0.59%-0.17x0.79x
VTAK$3.03M+1.61%0.41x0.24x
HSDT$2.46M+0.50%-0.09x2.33x
HSCS$3.08M-2.37%-0.38x1.72x
VERO$2.41M+11.28%-0.04x0.25x

Bone Biologics Stock FAQ

What is Bone Biologics's quote symbol?

(NASDAQ: BBLG) Bone Biologics trades on the NASDAQ under the ticker symbol BBLG. Bone Biologics stock quotes can also be displayed as NASDAQ: BBLG.

If you're new to stock investing, here's how to buy Bone Biologics stock.

What is the 52 week high and low for Bone Biologics (NASDAQ: BBLG)?

(NASDAQ: BBLG) Bone Biologics's 52-week high was $4.25, and its 52-week low was $0.71. It is currently -80.19% from its 52-week high and 18.93% from its 52-week low.

How much is Bone Biologics stock worth today?

(NASDAQ: BBLG) Bone Biologics currently has 3,271,042 outstanding shares. With Bone Biologics stock trading at $0.84 per share, the total value of Bone Biologics stock (market capitalization) is $2.75M.

Bone Biologics stock was originally listed at a price of $1,230.01 in Mar 31, 2016. If you had invested in Bone Biologics stock at $1,230.01, your return over the last 8 years would have been -99.93%, for an annualized return of -59.78% (not including any dividends or dividend reinvestments).

How much is Bone Biologics's stock price per share?

(NASDAQ: BBLG) Bone Biologics stock price per share is $0.84 today (as of Mar 27, 2025).

What is Bone Biologics's Market Cap?

(NASDAQ: BBLG) Bone Biologics's market cap is $2.75M, as of Mar 28, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bone Biologics's market cap is calculated by multiplying BBLG's current stock price of $0.84 by BBLG's total outstanding shares of 3,271,042.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.